NCT04803851 2023-06-22
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
Clinical Trials
9 trialsNCT04236362 2021-01-12
A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04273815 2020-07-08
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT03706287 2020-04-06
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Unknown
NCT04157491 2019-11-08
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT03825705 2019-10-31
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04004975 2019-07-02
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib
Shandong Cancer Hospital and Institute
Phase 1/2 Unknown
NCT03416517 2019-02-15
Anlotinib and Irinotecan for Ewing Sarcoma
Peking University People's Hospital
Phase 1/2 Unknown
NCT03639467 2018-09-18
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
ChineseAMS
Phase 1/2 Unknown